Categories
Archives
Receive Email Updates
-
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
Tag Archives: The State of Patent Eligibility
Solicitor General’s Briefs Encourage Supreme Court to Put s. 101 Back on Track
Earlier this year, the Supreme Court issued orders to the Solicitor General to weigh in on whether or not the Court should grant cert. in two high profile Fed. Cir. decisions: Hikma Pharm. USA Inc, v. Vanda Pharm. Inc., No. … Continue reading
Posted in Patent Eligible Subject Matter
Tagged 101, Supreme Court, The State of Patent Eligibility
Leave a comment
October 2019 Update: Subject Matter Eligibility – A Closer Look
Guest post from Edward Sandor. Warren Woessner also posted a blog about the Updated Guidance on October 21. On October 17, 2019, the USPTO published an October 2019 Patent Eligibility Guidance Update to the earlier 2019 Revised Patent Subject Matter … Continue reading
Posted in Patent Eligible Subject Matter
Tagged Alice, The State of Patent Eligibility, USPTO
Leave a comment
Athena’s “Questionable” Petition for Cert.
On October 1st, Athena filed a petition for a writ of certiorari to the Supreme Court following the Fed. Cir.’s fractured denial for its petition for rehearing en banc in Amgen v. Mayo. The original request for rehearing en banc … Continue reading
Senate Subcommittee Hearing of Patent Eligibility Wrap Up – Now What?
In my first post on the Subcommittee Hearings held last week, I noted the absence of many witnesses from the life science industry, as opposed to groups such as IPO, AIPLA, BIO, ACLU and PhMA. The third and final panel, … Continue reading